vs
SouthState Bank Corp（SSB）与UNITED THERAPEUTICS Corp（UTHR）财务数据对比。点击上方公司名可切换其他公司
UNITED THERAPEUTICS Corp的季度营收约是SouthState Bank Corp的1.2倍（$790.2M vs $661.7M），UNITED THERAPEUTICS Corp净利率更高（46.1% vs 34.1%，领先12.0%），过去两年SouthState Bank Corp的营收复合增速更高（37.4% vs 8.0%）
SouthState Bank总部位于美国佛罗里达州温特黑文，是银行控股公司SouthState Corporation旗下的银行子公司。截至2025年5月26日，该行已在南卡罗来纳、北卡罗来纳、佐治亚、佛罗里达、阿拉巴马、弗吉尼亚、科罗拉多、得克萨斯八州设有371家营业网点，为当地客户提供各类银行金融服务。
United Therapeutics是美国生物技术企业，专注开发包含异种移植在内的器官移植相关药物与技术，多款产品布局肺部疾病及器官制造赛道，双总部位于马里兰州银泉与北卡罗来纳州三角研究园，在美加多地设有研发及运营分支机构。
SSB vs UTHR — 直观对比
营收规模更大
UTHR
是对方的1.2倍
$661.7M
净利率更高
UTHR
高出12.0%
34.1%
两年增速更快
SSB
近两年复合增速
8.0%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $661.7M | $790.2M |
| 净利润 | $225.8M | $364.3M |
| 毛利率 | — | 86.9% |
| 营业利润率 | 15.1% | 45.1% |
| 净利率 | 34.1% | 46.1% |
| 营收同比 | — | 7.4% |
| 净利润同比 | 153.5% | 20.9% |
| 每股收益（稀释后） | $2.28 | $7.66 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收SSBUTHR
| Q1 26 | $661.7M | — | ||
| Q4 25 | $581.1M | $790.2M | ||
| Q3 25 | $599.7M | $799.5M | ||
| Q2 25 | $577.9M | $798.6M | ||
| Q1 25 | $544.5M | $794.4M | ||
| Q4 24 | $369.8M | $735.9M | ||
| Q3 24 | $351.5M | $748.9M | ||
| Q2 24 | $350.3M | $714.9M |
净利润SSBUTHR
| Q1 26 | $225.8M | — | ||
| Q4 25 | $247.7M | $364.3M | ||
| Q3 25 | $246.6M | $338.7M | ||
| Q2 25 | $215.2M | $309.5M | ||
| Q1 25 | $89.1M | $322.2M | ||
| Q4 24 | $144.2M | $301.3M | ||
| Q3 24 | $143.2M | $309.1M | ||
| Q2 24 | $132.4M | $278.1M |
毛利率SSBUTHR
| Q1 26 | — | — | ||
| Q4 25 | — | 86.9% | ||
| Q3 25 | — | 87.4% | ||
| Q2 25 | — | 89.0% | ||
| Q1 25 | — | 88.4% | ||
| Q4 24 | — | 89.7% | ||
| Q3 24 | — | 88.9% | ||
| Q2 24 | — | 89.1% |
营业利润率SSBUTHR
| Q1 26 | 15.1% | — | ||
| Q4 25 | 54.3% | 45.1% | ||
| Q3 25 | 53.6% | 48.6% | ||
| Q2 25 | 48.8% | 45.6% | ||
| Q1 25 | 22.3% | 48.2% | ||
| Q4 24 | 50.7% | 48.6% | ||
| Q3 24 | 53.1% | 45.8% | ||
| Q2 24 | 49.3% | 44.7% |
净利率SSBUTHR
| Q1 26 | 34.1% | — | ||
| Q4 25 | 42.6% | 46.1% | ||
| Q3 25 | 41.1% | 42.4% | ||
| Q2 25 | 37.2% | 38.8% | ||
| Q1 25 | 16.4% | 40.6% | ||
| Q4 24 | 39.0% | 40.9% | ||
| Q3 24 | 40.7% | 41.3% | ||
| Q2 24 | 37.8% | 38.9% |
每股收益（稀释后）SSBUTHR
| Q1 26 | $2.28 | — | ||
| Q4 25 | $2.47 | $7.66 | ||
| Q3 25 | $2.42 | $7.16 | ||
| Q2 25 | $2.11 | $6.41 | ||
| Q1 25 | $0.87 | $6.63 | ||
| Q4 24 | $1.88 | $6.23 | ||
| Q3 24 | $1.86 | $6.39 | ||
| Q2 24 | $1.73 | $5.85 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $2.9B | $2.9B |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $9.0B | $7.1B |
| 总资产 | $68.0B | $7.9B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资SSBUTHR
| Q1 26 | $2.9B | — | ||
| Q4 25 | — | $2.9B | ||
| Q3 25 | — | $2.8B | ||
| Q2 25 | — | $3.0B | ||
| Q1 25 | — | $3.3B | ||
| Q4 24 | — | $3.3B | ||
| Q3 24 | — | $3.3B | ||
| Q2 24 | — | $3.0B |
股东权益SSBUTHR
| Q1 26 | $9.0B | — | ||
| Q4 25 | $9.1B | $7.1B | ||
| Q3 25 | $9.0B | $6.6B | ||
| Q2 25 | $8.8B | $7.2B | ||
| Q1 25 | $8.6B | $6.8B | ||
| Q4 24 | $5.9B | $6.4B | ||
| Q3 24 | $5.9B | $6.1B | ||
| Q2 24 | $5.7B | $5.7B |
总资产SSBUTHR
| Q1 26 | $68.0B | — | ||
| Q4 25 | $67.2B | $7.9B | ||
| Q3 25 | $66.0B | $7.4B | ||
| Q2 25 | $65.9B | $7.9B | ||
| Q1 25 | $65.1B | $7.7B | ||
| Q4 24 | $46.4B | $7.4B | ||
| Q3 24 | $46.1B | $7.1B | ||
| Q2 24 | $45.5B | $6.7B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $346.2M |
| 自由现金流经营现金流 - 资本支出 | — | $173.3M |
| 自由现金流率自由现金流/营收 | — | 21.9% |
| 资本支出强度资本支出/营收 | — | 21.9% |
| 现金转化率经营现金流/净利润 | — | 0.95× |
| 过去12个月自由现金流最近4个季度 | — | $1.0B |
8季度趋势，按日历期对齐
经营现金流SSBUTHR
| Q1 26 | — | — | ||
| Q4 25 | $232.1M | $346.2M | ||
| Q3 25 | $122.4M | $562.1M | ||
| Q2 25 | $72.6M | $191.7M | ||
| Q1 25 | $-126.3M | $461.2M | ||
| Q4 24 | $354.3M | $341.2M | ||
| Q3 24 | $-246.8M | $377.2M | ||
| Q2 24 | $126.8M | $232.2M |
自由现金流SSBUTHR
| Q1 26 | — | — | ||
| Q4 25 | $215.5M | $173.3M | ||
| Q3 25 | $101.7M | $351.6M | ||
| Q2 25 | $52.5M | $129.5M | ||
| Q1 25 | $-139.1M | $386.3M | ||
| Q4 24 | $340.9M | $254.5M | ||
| Q3 24 | $-254.2M | $300.7M | ||
| Q2 24 | $117.3M | $187.1M |
自由现金流率SSBUTHR
| Q1 26 | — | — | ||
| Q4 25 | 37.1% | 21.9% | ||
| Q3 25 | 17.0% | 44.0% | ||
| Q2 25 | 9.1% | 16.2% | ||
| Q1 25 | -25.5% | 48.6% | ||
| Q4 24 | 92.2% | 34.6% | ||
| Q3 24 | -72.3% | 40.2% | ||
| Q2 24 | 33.5% | 26.2% |
资本支出强度SSBUTHR
| Q1 26 | — | — | ||
| Q4 25 | 2.9% | 21.9% | ||
| Q3 25 | 3.5% | 26.3% | ||
| Q2 25 | 3.5% | 7.8% | ||
| Q1 25 | 2.4% | 9.4% | ||
| Q4 24 | 3.6% | 11.8% | ||
| Q3 24 | 2.1% | 10.2% | ||
| Q2 24 | 2.7% | 6.3% |
现金转化率SSBUTHR
| Q1 26 | — | — | ||
| Q4 25 | 0.94× | 0.95× | ||
| Q3 25 | 0.50× | 1.66× | ||
| Q2 25 | 0.34× | 0.62× | ||
| Q1 25 | -1.42× | 1.43× | ||
| Q4 24 | 2.46× | 1.13× | ||
| Q3 24 | -1.72× | 1.22× | ||
| Q2 24 | 0.96× | 0.83× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
SSB
| Net Interest Income | $561.6M | 85% |
| Noninterest Income | $100.1M | 15% |
UTHR
| Tyvaso DPI | $338.6M | 43% |
| Remodulin | $128.0M | 16% |
| Nebulized Tyvaso | $125.7M | 16% |
| Orenitram | $121.2M | 15% |
| Unituxin | $62.3M | 8% |
| Adcirca | $7.8M | 1% |
| Other | $6.6M | 1% |
